Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01241773
Other study ID # CR017494
Secondary ID
Status Completed
Phase Phase 1
First received October 21, 2010
Last updated November 7, 2012
Start date October 2010
Est. completion date April 2011

Study information

Verified date November 2012
Source Tibotec Pharmaceuticals, Ireland
Contact n/a
Is FDA regulated No
Health authority Ireland: Irish Agriculture and Food Development Authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the steady-state pharmacokinetics of efavirenz or raltegravir , and vice versa. Steady state is a term which means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Efavirenz and raltegravir are two antiretroviral drugs for treatment of human deficiency virus (HIV) infection. Pharmacokinetics (pk) means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.


Description:

TMC435 is being investigated for treatment of chronic hepatitis C virus (HCV) infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin). About 30% of all HIV infected patients are co-infected with HCV and need treatment for both infections. The results of this study will provide dosing recommendations for coadministration of TMC435 and efavirenz or raltegravir in HIV-HCV co-infected patients. This is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), randomized (sequence of treatment with study medications is assigned by chance), crossover trial in 48 healthy volunteers to investigate the pharmacokinetic interaction between TMC435 and an antiretroviral agent (efavirenz or raltegravir), at steady state. The volunteers are being allocated to one of two panels. In Panel 1, volunteers will receive three treatments (treatment A-B-C) in a randomized order. Volunteers will receive TMC435 150 mg q.d., efavirenz 600 mg q.d. and efavirenz 600 mg q.d. + TMC435 150 mg q.d., respectively. All treatments will be administered for 14 days. There will be a washout period (a period where no study drug will be taken in view of having all the medication eliminated from the body before starting a new treatment) of at least 14 days between last intake of study medication in one session and first intake of study medication in the subsequent session. In Panel 2, volunteers will receive three treatments (treatment D-E-F) in a randomized order. Volunteers will receive TMC435 150 mg q.d., raltegravir 400 mg b.i.d. and raltegravir 400 mg b.i.d. + TMC435 150 mg q.d., respectively. All treatments will be administered for 7 days. There will be a washout period of at least 7 days. Pharmacokinetic profiles of all three compounds will be determined through blood samples taken at regular intervals during the study. Safety and tolerability will be assessed during the study period and in follow-up. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, before medication intake on Days 1 and 14 and on Day 15 in each session of Panel 1, before medication intake on Days 1 and 7 and on Day8 in each session of Panel 2, 6 hours post dose on Day14 and Day7 in Panel 1 and 2, respectively and at the 2 follow up visits at 1 week and 4-5 weeks after last dose of study medication in the last session. A physical examination will be performed at screening, on Day-1 (= day before first medication intake in each session for both panels) and on Day15 in Panel 1, on Day-1 and on Day8 of Panel 2 and during the 2 follow up visits. Each volunteer will receive 3 treatments for 14 or 7 days (Panel 1 and 2, respectively), minimum 14 or 7 days apart from each other (Panel 1 and 2, respectively). Volunteers in Panel 1 will take oral TMC435 150 mg q.d., oral efavirenz 600 mg q.d. and combined. Volunteers in Panel 2 will take oral TMC435 150 mg q.d., oral raltegravir 400 mg b.i.d. and combined.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date April 2011
Est. primary completion date April 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- No-smoker for at least 3 months

- Body Mass Index of 18.0 to 30.0 kg/m2

- Healthy based on a medical evaluation including medical history, physical examination, blood tests and electrocardiogram

Exclusion Criteria:

- Infection with Hepatitis A, B or C Virus

- Infection with the Human Immunodeficiency Virus (HIV)

- History of, or any current medical condition which could impact the safety of the participant in the study

- Having previously participated in a multiple-dose trial with TMC435

- Having previously participated in more than 3 single-dose trials with TMC435.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
raltegravir
One 400 mg tablet twice daily for 7 days
TMC435 + raltegravir
Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
TMC435
Two 75 mg capsules once daily for 7 days
TMC435 + efavirenz
Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
TMC435
Two 75 mg capsules once daily for 14 days
efavirenz
One 600 mg tablet once daily for 14 days

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tibotec Pharmaceuticals, Ireland

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absorption of TMC435 following co-administration with efavirenz, and vice versa. Measured on Day1, 12, 13, 14, 15, 16, 17 and 18 for both drugs in eaach treatment in Panel 1. No
Primary Absorption of TMC435 following co-administration with raltegravir, and vice versa. Measured on Day1, 5, 6, and 7 for both drugs in each treatment of Panel2 and on Day8-11 for TMC435 only in treatment D and F in Panel 2. No
Secondary Number of participants with Adverse Events as a measure of Safety and Tolerability - TMC435 and efavirenz. 98 to 103 days (till and including last safety follow-up visit) for Panel 1 No
Secondary Number of participants with Adverse Events as a measure of Safety and Tolerability - TMC435 and raltegravir. 63 to 68 days (till and including last safety follow-up visit) for Panel 2 No
See also
  Status Clinical Trial Phase
Completed NCT02907996 - Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Not yet recruiting NCT02893046 - HCV Care Pathway in Ile-de-France N/A
Completed NCT01428063 - Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials Phase 2
Completed NCT01396005 - A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123) Phase 1
Completed NCT01195181 - Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Phase 4
Completed NCT00219999 - Hepatitis C Virus and the Humoral Immune System N/A
Completed NCT02243293 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection Phase 2/Phase 3
Completed NCT02265237 - A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) Phase 3
Not yet recruiting NCT06104046 - Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis
Completed NCT02604017 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection Phase 3
Withdrawn NCT00947245 - Japanese Bridging Study Conducted in the United States Phase 1
Completed NCT01713283 - Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection Phase 2
Completed NCT01458535 - A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Phase 2
Completed NCT01479881 - A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus Phase 1
Completed NCT01193361 - Ph IIA Study (SOC +/- NS5B) Phase 2
Completed NCT01006031 - Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4 Phase 2/Phase 3
Completed NCT00819026 - Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors N/A
Completed NCT00382798 - Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin Phase 1/Phase 2
Completed NCT02592057 - Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India